Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.580
+0.020 (3.57%)
At close: Jun 26, 2026, 4:00 PM EDT
0.590
+0.010 (1.66%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Context Therapeutics Employees
Context Therapeutics had 15 employees as of December 31, 2025. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,681,795
Market Cap
53.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15 | 3 | 25.00% |
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | 8 | 800.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| Xilio Therapeutics | 76 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| PDS Biotechnology | 21 |
| Instil Bio | 17 |
| Apollomics | 14 |
| Dogwood Therapeutics | 8 |
CNTX News
- 11 days ago - Context Therapeutics price target lowered to $4 from $8 at Maxim - TheFly
- 12 days ago - Context Therapeutics selloff brings buying opportunity, says JonesResearch - TheFly
- 12 days ago - Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright - TheFly
- 12 days ago - Context Therapeutics Transcript: Study result - Transcripts
- 12 days ago - Context Therapeutics Press release: Study result - Filings
- 12 days ago - Context Therapeutics Slides: Study result - Filings
- 12 days ago - Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial - TheFly
- 12 days ago - Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - GlobeNewsWire